Xenon Pharmaceuticals reports 90.9% seizure reduction in X-TOLE OLE study.

Xenon Pharmaceuticals reports significant reductions in seizure frequency in a long-term trial of azetukalner, with 38% of participants achieving at least one year of seizure freedom. Four real-world study posters highlight the burden of depression and antiepileptic medication titration on people with epilepsy. Preclinical data suggests potential to improve motor function in Dravet syndrome through potentiation of NaV1.1.